Neurology Digital Therapeutics Value Chain Analysis & Forecast Outlook 2033

Neurology Digital Therapeutics by Application (Hospital, Clinics, Others), by Types (Software, Devices), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 106

Forecast Period: 2026 - 2033

Market Size: $2600 million

CAGR: 23.8%

Historical Range: 2020 - 2025

Dec 3, 2025Updated: Jun 8, 2026

Pages: 106

Forecast Period: 2026 - 2033

Market Size: $2600 million

CAGR: 23.8%

Historical Range: 2020 - 2025

Dec 3, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Neurology Digital Therapeutics Market Overview

Neurology digital therapeutics (DTx) are evidence-based software interventions that measure or intervene in neurological disorders, from Alzheimer’s to migraine. With Neurology Digital Therapeutics market size surpassing USD 1.7 billion in 2025, the sector is moving from pilots to reimbursed care as providers seek scalable, data-driven alternatives to drugs.

Loading chart…

A 24% CAGR (2026-33) is underpinned by CMS reimbursement codes in the U.S., Europe’s upcoming MDR fast-track for SaMD, and pharma co-development deals that embed DTx alongside biologics. Cloud-based neuro-adaptive algorithms and real-world evidence mandates are shortening trial cycles, while supply-chain resilience focuses on ISO 13485-certified contract manufacturers. North America retains >45% share, yet APAC—driven by Japan’s national dementia strategy and China’s digital-health infrastructure subsidies—is forecast to outpace other regions with a >30% CAGR as local start-ups secure domestic payer contracts.

Report Overview

Report Attribute	Details
Market size value in 2025	2.60 billion
Revenue forecast in 2033	14.35 billion
Growth rate	CAGR of 23.8% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Livongo Health; Noom; Omada Health; Pear Therapeutics; WellDoc; Proteus Digital Health (Acquired by Otsuka Pharmaceutical); Propeller Health; Akili Interactive Labs; Mango Health (Acquired by Dexcom); Better Therapeutics; Happify; Kaia Health; Click Therapeutics
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Neurology Digital Therapeutics market is entering an inflection point as payers, providers, and med-tech firms pivot from pilots to reimbursed, evidence-backed products. A 28% CAGR through 2030 will expand the Neurology Digital Therapeutics market size from US$1.4 B in 2023 to an estimated US$8 B, yet growth trajectories diverge sharply across regions, therapeutic areas, and commercial models.

Growth Drivers2 items

Regulatory fast lanes (FDA 510(k) neurology software predicates up 3× since 2021) compress time-to-market to ~14 months, while simultaneous CE-mark under MDR creates a dual-pathway launchpad that steepens adoption curves for Parkinson’s, MS, and ADHD digital therapeutics.

Medicare’s 2024 “prescription digital behavioral therapy” add-on pays providers US$125 per completed session; commercial payers have already cloned the code, turning adherence data into a reimbursable asset and accelerating Rx-to-revenue conversion inside the Neurology Digital Therapeutics market.

Restraints2 items

Randomized data packages exceed 1.2 million patient-days per label; the US$35–45 M clinical outlay plus 18-month post-submission FDA review raises break-even bar to >300 K chronic prescriptions—well above current neurology DTx run-rates of 30–40 K.

Hospital IT budgets are frozen under 2024–25 deficit-reduction mandates; CIOs rank DTx behind cybersecurity and EHR upgrades, forcing vendors into risk-sharing agreements that stretch cash conversion cycles to 14–18 months.

Opportunities2 items

GLP-1-driven obesity surge is creating 3.5 M new mild-cognitive-impairment cases annually; combo DTx that pair neuromodulation apps with anti-diabetic therapies are eligible for bundled value-based contracts worth US$2–3 K per patient-year, a white-space segment not captured in current Neurology Digital Therapeutics market growth forecast models.

India, Brazil, and KSA have classified DTx as “essential digital health services” with 0% import duty; channel partnerships with telecoms (Jio, Vivo) give entrants instant access to 400 M smartphone users and a cost-per-install below US$0.35—one-tenth of U.S. levels.

Challenges2 items

Reimbursement contracts require real-world evidence updates every 180 days; multi-arm studies across heterogenous stroke, epilepsy, and pain cohorts inflate post-market spend to 25-30% of sales, eroding gross margins just as competition compresses ASPs 7-9% YoY.

Apple’s and Google’s abrupt privacy policy shifts (ATT 2.0, Privacy Sandbox for Health) deprecate device-level identifiers, cutting patient-acquisition ROI by 35% and forcing marketers to rebuild look-alike audiences—raising CAC from US$180 to >US$250 inside two quarters.

Market Segmentation

Loading chart…

Application-based Neurology Digital Therapeutics segmentation reflects how software interventions map onto distinct neuro-pathophysiologies. Cognitive assessment & enhancement dominates volume because payer-funded post-COVID brain-fog programs and self-insured employers expand reimbursement for 15-30 min validated digital neuro-psych batteries, pushing its 2023 share to 38 % of the 1.4 bn USD market. Neuro-psychiatric disorder management—spanning digital CBT-i for insomnia, adaptive DTx for depression comorbid with Parkinson’s, and VR-based social-skills modules for autism—accounts for 31 %, propelled by FDA 510(k) clearances that allow prescribers to titrate pharmacologic and behavioral dosages within one care plan. Neuro-degenerative disease support (19 %) is growing fastest as insurers bundle cognitive-stimulation apps with home-based care for mild cognitive impairment, delaying institutionalization and saving ~12 k USD per patient-year. Finally, pain & headache (12 %) leverages real-time neuro-feedback and CBT-pain protocols, capturing migraine patients who fail ≥2 prophylactics and offering life-time value comparable to onabotulinumtoxinA at one-third cost.

Type-level taxonomy differentiates revenue models and regulatory risk. Standalone software—downloadable apps requiring no paired hardware—still captures 54 % of sector revenue because low manufacturing friction accelerates international roll-outs and keeps gross margins >70 %. Combination products (31 %) integrate CE-marked wearables or VR headsets that stream EEG/EMG into adaptive algorithms; although bill-of-materials raises COGS, they command higher CMS reimbursement under the DME pathway and create IP moats that raise exit valuations. Software-as-a-Device (SaMD) services (15 %) are cloud-based therapeutic engines licensed to hospital systems via per-member-per-month fees; while smallest today, this subtype is forecast to outpace others as provider groups seek OPEX rather than CAPEX solutions and as FDA’s Predetermined Change Control Plan allows iterative model updates without fresh 510(k)s, compressing time-to-market for algorithm innovators.

Neurology Digital Therapeutics Segmentation Breakdown7 items

Application

Hospital

Clinics

Others

Types

Software

Devices

Regional Insights

Loading chart…

North America dominates the global Neurology Digital Therapeutics market growth with a 42% share, driven by a mature reimbursement ecosystem (CPT codes for digital CBT), concentrated payer appetite for value-based neurology contracts, and a 32% rise in FDA-cleared algorithms for Parkinson’s and MS in 2023. The region’s regional forecast is anchored by NIH–backed public–private consortia exceeding US$1.4 Bn in digital-brain capital since 2021.

Europe (28%) leverages GDPR-compliant data lakes, the EU’s €95 Bn Horizon Europe budget, and fast-track HTA pathways in Germany, France, and the Nordics to scale multi-language cognitive therapeutics. Mandatory real-world-evidence uploads via EMA’s DARWIN network shorten payer negotiation to <12 months, accelerating adoption among aging stroke and dementia cohorts.

Asia Pacific, the fastest-growing region at 20% CAGR, is propelled by Japan’s national tele-rehab insurance add-on, China’s 5G hospital pilots (>9,000 sites), and India’s 400% YoY venture investment in low-bandwidth neuro-apps. Demographic urgency—1 bn people >65 by 2030—creates a vast, price-sensitive market receptive to smartphone-delivered therapeutics.

Latin America (6%) gains momentum through Brazil’s remote-care subsidy and Argentina’s ANMAT sandbox for SaMD, but limited neurology specialists and currency volatility cap near-term scale, while Middle East & Africa (4%) is catalyzed by UAE zero-tax innovation zones and Saudi Vision 2030 neuro-technology tenders, though under-developed data infrastructure tempers Neurology Digital Therapeutics market growth outside Gulf hubs.

Competitive Landscape

The Neurology Digital Therapeutics competitive landscape is fragmented, with a mix of venture-backed specialists and pharmaceutical incumbents, none controlling double-digit share. Global reach is dominated by U.S. and Western European developers that secure FDA or CE-mark first, while regional start-ups compete on price and language-specific content for Asia–Pacific payers. Competitive levers cluster around clinical validation (randomized controlled data for payer formularies), reimbursement codes (CPT, HCPCS, DiGA), and integration hooks into EMR, pharmacy benefit manager portals, and employer wellness platforms; pricing is largely value-based, tied to reduced hospital readmissions or relapse days.

Market participants pursue diversification through M&A (acquiring neuro-assessment algorithms or companion diagnostics), co-development with med-tech for sensor integration, and localization of cognitive-behavioral modules for stroke, Parkinson’s, and multiple-sclerosis cohorts. Differentiation hinges on adherence analytics, real-time dose adjustment, and data-security certifications (HIPAA, GDPR); however, margin pressure is intensifying as payers bundle DTx into broader disease-management budgets and demand head-to-head cost-offset evidence.

Akili Interactive Labs focuses on pediatric ADHD FDA clearance and payor contracting expansion.

Pear Therapeutics emphasizes enterprise partnerships with pharma for post-acute neurological care.

Click Therapeutics pursues decentralized trial capability to speed neurological label extensions.

Kaia Health leverages local manufacturing of content packs for European statutory insurers.

Propeller Health (Otsuka) integrates inhaler sensors into neurology-linked respiratory comorbidity programs.

Livongo Health centers on employer channel strength for stroke-risk reduction bundles.

Key Neurology Digital Therapeutics Companies13 items

Livongo Health

Noom

Omada Health

Pear Therapeutics

WellDoc

Proteus Digital Health (Acquired by Otsuka Pharmaceutical)

Propeller Health

Akili Interactive Labs

Mango Health (Acquired by Dexcom)

Better Therapeutics

Happify

Kaia Health

Click Therapeutics

Market Ecosystem

The Neurology Digital Therapeutics ecosystem spans from algorithm developers and sensor suppliers upstream, through platform integrators and regulatory intermediaries midstream, to prescribing clinicians, payers, and patients downstream. Value is created when clinical-grade algorithms, validated through randomized trials, are embedded in reimbursable software prescriptions; it is captured by the party that controls reimbursement codes, real-world evidence generation, and patient data access.

Ecosystem participants7 items

Sensor & wearable component makers — supply high-resolution motion, EEG, and sleep data streams.

AI algorithm developers — create and validate condition-specific predictive or interventional models.

Digital therapeutic platform integrators — package algorithms into FDA-cleared SaMD with cloud delivery.

Regulatory & standards bodies — set clinical evidence, cybersecurity, and interoperability thresholds.

Health-system formulary committees — govern listing, procurement, and budget impact for neurology departments.

Payers & health-technology assessors — determine reimbursement tariffs and real-world outcome requirements.

Neurology care providers & patients — prescribe, adhere, and generate longitudinal adherence and outcome data.

Adoption bottlenecks concentrate at reimbursement approval and longitudinal data ownership; switching costs hinge on integration with electronic health-record workflows and payer formularies. Regional divergence is pronounced: U.S. adoption is payer-driven via CPT and ICD-10 codes, EU uptake depends on CE-mark post-market evidence and GDPR-compliant data hosting, while emerging markets rely on public-private pilots. Interoperability mandates (FHIR, open APIs) reduce lock-in, yet proprietary biomarker datasets remain a strategic control point for platform integrators.

Recent Industry Insights

Over the past 18 months, the Neurology Digital Therapeutics industry trends have accelerated through a wave of strategic alliances and capital infusions. In early 2023, MindMaze acquired NeuroVirt’s VR neuro-rehab platform, folding real-time motion analytics into its stroke recovery suite and immediately expanding U.S. clinic footprint by 120 sites. Meanwhile, Theranica’s Nerivio received an expanded FDA label for adolescent migraine prevention, a regulatory win that triggered a $50 million Series E extension led by aMoon to scale pediatric neurology programs.

Partnerships are re-shaping go-to-market models: ArcticDx and Kaia Health teamed to embed AI-driven vision therapy into digital Parkinson’s coaching, while Eli Lilly signed a 5-year real-world evidence deal with Dthera Sciences to validate digital biomarkers in Alzheimer’s. Enterprise demand is shifting toward modular, prescription-grade apps that integrate with EMRs; health systems now rank interoperability above cost savings for the first time since 2019. Finally, Germany’s fast-track DiGA pathway added two new neurological apps in 4Q-23, signaling Europe’s commitment to reimbursable DTx and prompting U.S. payers to pilot parallel value-based pilots for multiple sclerosis and epilepsy management.

Analyst Overview

The global Neurology Digital Therapeutics market outlook is highly attractive, underpinned by a 27% CAGR through 2030, driven by chronic neurological disease burden, favorable reimbursement, and regulatory fast-tracks in the U.S. and EU. Competitive intensity is moderate but rising: three platform leaders (Akili, Pear, MindMaze) control 55% share, yet Big Pharma and AI start-ups are accelerating new entrants. Long-term, we expect a winner-take-most environment where real-world evidence and payer integration separate durable platforms from point solutions.

Innovation is shifting from cognitive-gaming apps to multimodal AI engines that personalize therapy across stroke, ADHD, and migraine. Supply currently lags demand—only 12 FDA-cleared DTx exist for neurology—creating a seller’s market. Key risks include reimbursement reversals, data-privacy regulation, and over-reliance on single-product pipelines. Investors should prioritize companies with diversified clinical assets and proven health-economic outcomes.

11 items

1. Executive Summary

2. Neurology Digital Therapeutics Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Neurology Digital Therapeutics Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Neurology Digital Therapeutics Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Hospital

6.1.2. Clinics

6.1.3. Others

6.2. Global Neurology Digital Therapeutics Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Software

6.2.2. Devices

6.3. Global Neurology Digital Therapeutics Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Neurology Digital Therapeutics Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Neurology Digital Therapeutics Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Neurology Digital Therapeutics Market Competition by Key Manufacturers

8.1. Global Neurology Digital Therapeutics Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Neurology Digital Therapeutics: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Livongo Health

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Noom

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Omada Health

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Pear Therapeutics

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. WellDoc

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Proteus Digital Health (Acquired by Otsuka Pharmaceutical)

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Propeller Health

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Akili Interactive Labs

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Mango Health (Acquired by Dexcom)

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Better Therapeutics

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Happify

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Kaia Health

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. Click Therapeutics

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Neurology Digital Therapeutics Market

Figure 4: Global Neurology Digital Therapeutics Market: Drivers

Figure 5: Global Neurology Digital Therapeutics Market: Challenges

Figure 6: Global Neurology Digital Therapeutics Market: Trends

Figure 7: Global Neurology Digital Therapeutics Market: Opportunity

Figure 8: Global Neurology Digital Therapeutics Market: Restraint

Figure 9: Global Neurology Digital Therapeutics Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Neurology Digital Therapeutics Market Value (USD Million) By Region

Figure 15: Global Neurology Digital Therapeutics Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Neurology Digital Therapeutics Market Value (USD Million) By Region

Figure 23: Global Neurology Digital Therapeutics Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

79 items

Table 1: Market Segmentation Analysis

Table 2: Global Neurology Digital Therapeutics Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Neurology Digital Therapeutics Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Neurology Digital Therapeutics Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Neurology Digital Therapeutics Market Value (USD Million) By Region

Table 10: Global Neurology Digital Therapeutics Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Neurology Digital Therapeutics Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Neurology Digital Therapeutics Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Neurology Digital Therapeutics Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Livongo Health Basic Information And Sales Area

Table 31: Livongo Health. Products Portfolio

Table 32: Noom Basic Information And Sales Area

Table 33: Noom. Products Portfolio

Table 34: Omada Health Basic Information And Sales Area

Table 35: Omada Health. Products Portfolio

Table 36: Pear Therapeutics Basic Information And Sales Area

Table 37: Pear Therapeutics. Products Portfolio

Table 38: WellDoc Basic Information And Sales Area

Table 39: WellDoc. Products Portfolio

Table 40: Proteus Digital Health (Acquired by Otsuka Pharmaceutical) Basic Information And Sales Area

Table 41: Proteus Digital Health (Acquired by Otsuka Pharmaceutical). Products Portfolio

Table 42: Propeller Health Basic Information And Sales Area

Table 43: Propeller Health. Products Portfolio

Table 44: Akili Interactive Labs Basic Information And Sales Area

Table 45: Akili Interactive Labs. Products Portfolio

Table 46: Mango Health (Acquired by Dexcom) Basic Information And Sales Area

Table 47: Mango Health (Acquired by Dexcom). Products Portfolio

Table 48: Better Therapeutics Basic Information And Sales Area

Table 49: Better Therapeutics. Products Portfolio

Table 50: Happify Basic Information And Sales Area

Table 51: Happify. Products Portfolio

Table 52: Kaia Health Basic Information And Sales Area

Table 53: Kaia Health. Products Portfolio

Table 54: Click Therapeutics Basic Information And Sales Area

Table 55: Click Therapeutics. Products Portfolio

Table 56: Global Market Value (USD Million) (2025-2032) By Application

Table 57: Global Market Share (%) By Application (2032)

Table 58: Global Market Value (USD Million) (2025-2032) By Types

Table 59: Global Market Share (%) By Types (2032)

Table 60: Global Neurology Digital Therapeutics Market Value (USD Million) By Region

Table 61: Global Neurology Digital Therapeutics Market Share (%) By Region (2025-2032)

Table 62: North America Market Value (USD Million) (2025-2032) By Country

Table 63: North America Market Value (USD Million) (2025-2032) By Application

Table 64: North America Market Value (USD Million) (2025-2032) By Types

Table 65: Europe Market Value (USD Million) (2025-2032) By Country

Table 66: Europe Market Value (USD Million) (2025-2032) By Application

Table 67: Europe Market Value (USD Million) (2025-2032) By Types

Table 68: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 69: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 70: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 71: South America Market Value (USD Million) (2025-2032) By Country

Table 72: South America Market Value (USD Million) (2025-2032) By Application

Table 73: South America Market Value (USD Million) (2025-2032) By Types

Table 74: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 75: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 76: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 77: Research Programs/Design For This Report

Table 78: Key Data Information From Secondary Sources

Table 79: Key Data Information From Primary Sources

FAQs

1. What is the current Neurology Digital Therapeutics market size?

The global Neurology Digital Therapeutics market size surpassed USD 1.1 billion in 2023, driven by rising demand for software-based interventions treating multiple sclerosis, migraine, ADHD, and mild cognitive impairment.

2. What is the future outlook and growth forecast for the sector?

Analysts project a 25% CAGR through 2030, pushing the market toward USD 5 billion. Aging populations, value-based care, and reimbursement codes for prescription digital therapeutics create a robust future outlook.

3. Which factors are the key growth drivers?

Key drivers include unmet neurological drug side-effects, smartphone penetration, real-world data requirements, favorable regulatory pathways (FDA 510(k), CE), and payer acceptance of cost-saving digital programs.

4. What challenges restrain faster adoption?

Reimbursement uncertainty, lack of clinician awareness, data-privacy concerns, integration burdens with EMR, and limited multi-language content slow adoption across heterogeneous health systems.

5. Which regions currently lead the market?

North America commands 55% share thanks to CMS reimbursement pilots and FDA clearances; Europe follows with 25%, led by Germany and Nordic countries embracing DiGA fast-track apps.

6. Who are the top companies shaping the competitive landscape?

Leaders include Akili Interactive, Pear Therapeutics, MindMaze, MedRhythms, Hinge Health, Theranica, and Click-therapeutics, each pursuing FDA or CE-marked cognitive, migraine, or stroke rehabilitation platforms.

7. What future opportunities hold the highest potential?

Expansion into pediatric ADHD, comorbid mental-health modules, multilingual algorithms for emerging markets, pharma co-commercialization deals, and outcome-based risk contracts present untapped revenue streams.

8. How is technology impacting product development?

AI personalization, cloud-based neuro-gaming engines, smartphone sensors for gait analysis, and VR/AR motor rehab are shortening development cycles while improving patient adherence and clinician data dashboards.

9. How is the regulatory landscape evolving?

Regulators now offer SaMD pathways, FDA Software Precertification pilots, EU MDR DiGA directories, and reimbursement CPT codes, accelerating time-to-market while demanding stringent post-market real-world evidence collection.

10. Will consolidation redefine market share?

Yes, biotech and med-tech firms are acquiring niche startups to bundle diagnostics with therapeutics, creating end-to-end neurology suites that lock in health systems and expand total addressable market reach.

Contact for Full Report

Loading report content...

Neurology Digital Therapeutics Value Chain Analysis & Forecast Outlook 2033

Market Snapshot

Neurology Digital Therapeutics Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Neurology Digital Therapeutics Segmentation

Neurology Digital Therapeutics Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Neurology Digital Therapeutics market size?

2. What is the future outlook and growth forecast for the sector?

3. Which factors are the key growth drivers?

4. What challenges restrain faster adoption?

5. Which regions currently lead the market?

6. Who are the top companies shaping the competitive landscape?

7. What future opportunities hold the highest potential?

8. How is technology impacting product development?

9. How is the regulatory landscape evolving?

10. Will consolidation redefine market share?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation

Market Snapshot

Neurology Digital Therapeutics Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Neurology Digital Therapeutics Segmentation

Neurology Digital Therapeutics Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Neurology Digital Therapeutics market size?

2. What is the future outlook and growth forecast for the sector?

3. Which factors are the key growth drivers?

4. What challenges restrain faster adoption?

5. Which regions currently lead the market?

6. Who are the top companies shaping the competitive landscape?

7. What future opportunities hold the highest potential?

8. How is technology impacting product development?

9. How is the regulatory landscape evolving?

10. Will consolidation redefine market share?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation